THERANEXUS: THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS

Lyon, France - Austin, TX, USA - 3 February 2022 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

Related Keywords

United States ,Houston ,Texas ,Baylor College Of Medicine ,France ,American ,Craig Benson ,Franck Mouthon ,National Organization For Rare Disorders ,National Institutes Of Health ,Drug Administration ,Batten Disease Foundation ,University Of Rochester Batten Center ,University Of Rochester ,Beyond Batten Disease Foundation ,North American ,Batten Disease ,Investigational New Drug ,Unified Batten Disease Rating Scale ,Texas Children ,National Institutes ,Rochester Batten Center ,Baylor College ,Rare Disorders ,Theranexus ,Bbdf ,Start ,Recruitment ,Hase ,Trial ,Thatten ,Disease ,Patients ,